NCT/Study#
NCT04150965 /
MMRC-089
A Phase I/II Assessment Of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) And Anti-TGIT (BMS-986207)
DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
